Treatment should begin with low doses, which should be increased gradually to avoid dehydration. Follow the patient's body weight.
During the treatment it is necessary to regularly monitor the electrolyte content in the blood plasma, eat foods rich in potassium, if necessary, prescribe potassium preparations.
Uregit® can be used in combination with other diuretics, the effect of which is summarized.
Additional administration of potassium is not required, many patients receiving diuretics. However, the introduction of potassium chloride or the use of potassium-sparing diuretics in patients with cirrhosis, nephrotic syndrome, or receiving digitalis preparations is recommended.Patients with normal renal function can be prescribed potassium preparations (with a regular control of the level of potassium in the blood plasma), tk. excess of potassium is excreted from the body. With renal failure, you can not administer potassium. Indications for the introduction of potassium are always set depending on the potassium content in the blood plasma.
If the patient develops diarrhea with large losses of fluid, then therapy should be discontinued.
During therapy it is recommended to carry out a systematic control of the electrolyte content in the blood plasma. Ethcarinic acid can potentiate concomitant antihypertensive therapy. At the same time there is a risk of development of orthostatic collapse.
With excessive diuresis, the drug should be discontinued until the water-electrolyte state stabilizes. With large losses of electrolytes, you can reduce the dose of the drug or temporarily discontinue therapy.
Patients with cirrhosis of the liver should be given the drug with great care, tk. Diuretic drugs increase the risk of hepatic coma, which can lead to death.
At a high risk of metabolic alkalosis (cirrhosis with ascites), the use of potassium-sparingdiuretics or the introduction of potassium chloride can weaken or prevent hypokalemia.
Loop diuretics reduce the level of magnesium ions in the blood.
Excessive fluid loss in the urine (rapid and pronounced weight loss) can lead to severe hypotension. In elderly patients with cardiac pathology, excessive diuresis may be accompanied by a decrease in the volume of circulating plasma and an increased risk of thromboembolic complications.
Care should be taken when prescribing the drug to patients prone to hypokalemia (some cases of diarrhea, chronic heart failure, taking digitalis preparations, ventricular arrhythmias in history, kidney disease with loss of potassium, hyperaldosteronism with normal renal function, systemic lupus erythematosus in history).
Effects of cardiac glycosides can be enhanced against a background of hypokalemia caused by diuretics.
With concomitant therapy, hormonal drugs that induce potassium loss (corticosteroids) require laboratory monitoring.
With renal edema, the effectiveness of this diuretic can be reduced by hypoproteinemia.
The risk of orthostatic hypotension may increase with the concomitant use of alcohol, barbiturates and diazepam.
During therapy with ethacrine acid, do not consume alcoholic beverages. Athletes should be aware of the fact that against the background of therapy with ethacrynic acid false positive results of doping control can be obtained.
In view of the lack of sufficient clinical data, UREIT® is not recommended for children.
Each tablet of the drug Uregit® contains 75 mg of lactose, therefore, this drug should not be taken by patients with rare hereditary intolerance to galactose, insufficiency of lactase and malabsorption syndrome of glucose and galactose.